Loading...
Publication
Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 72.34 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Description
Keywords
Peginterferão alfa-2a Peginterferon alfa-2a Ribavirina Ribavirin Infecção por HIV HIV infections Hepatite C Hepatitis C PARADIGM study
Citation
In: INTERNATIONAL LIVER CONGRESS. Annual Meeting of the European Association for the Study of the Liver, 45, Vienna, 14-18 April, 2010
Publisher
European Association for the Study of the Liver